In conclusion, we feel that data obtained through a clinically-driven protocol in two different PD models (neurotoxic and etiologic) and animal species (mouse and rat), convey a solid proof-of-concept that NOP receptor antagonists protect/rescue DA neurons from PD-like neurodegeneration. Although more evidence needs to be collected to claim that endogenous N/OFQ contributes to DA cell loss also in human PD, NOP receptor antagonists hold promise as symptomatic and disease-modifying agents in PD therapy
Parkinson's disease: no NOP, new hope
ARCURI, Ludovico;MERCATELLI, Daniela;MORARI, Michele
2017
Abstract
In conclusion, we feel that data obtained through a clinically-driven protocol in two different PD models (neurotoxic and etiologic) and animal species (mouse and rat), convey a solid proof-of-concept that NOP receptor antagonists protect/rescue DA neurons from PD-like neurodegeneration. Although more evidence needs to be collected to claim that endogenous N/OFQ contributes to DA cell loss also in human PD, NOP receptor antagonists hold promise as symptomatic and disease-modifying agents in PD therapyFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
